HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 10 of 13
Abemaciclib For Solid Tumors
The purpose of this study is to determine the highest safe dose of abemaciclib in patients with relapsed or treatment refractory solid tumors given in combination with the chemotherapy drugs, irinotecan and temozolomide (Part A) or in combination with just temozolomide (Part B).
ALRN-6924 in Pediatric Cancer
Evaluate the side effects and benefits of ALRN-6924 in patients with relapsed or treatment refractory solid tumor or brain tumor, and to determine the best dose of ALRN-6924 for children and adolescents.
BA3011 for advanced solid tumors
Copanlisib in Solid Tumors or Lymphoma
The purpose of this study is to find out what is the right dose of copanlisib in children and adolescents, and if your disease responds to this new drug.
Lurbinectedin in Ewing Sarcoma
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.
Lutathera in Somatostatin Neuroendocrine Tumors
This study involves taking a study drug called Lutathera.
The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.
Palbociclib, Irinotecan, and Temozolomide in Ewing Sarcoma
The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma.
Phase 1 Trial of CUDC-907
The overall goals of this study are to evaluate the side effects and benefits of CUDC-907 in patients with relapsed or treatment refractory solid tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for children and adolescents.
Ramucirumab for Desmoplastic Small Round Cell Tumor (DSRCT)
The overall goal of this study is to see how effective ramucirumab is when given in combination with cyclophosphamide and vinorelbine in children and young adults with desmoplastic small round cell tumor (DSRCT).